AOD-9604: A Rodent Signal That Did Not Cross Over

The short version

AOD-9604 stands for Anti-Obesity Drug 9604. It is a synthetic sixteen-amino-acid peptide modelled on the C-terminal end of human growth hormone — specifically the domain responsible for fat metabolism, not the domain that drives growth or raises IGF-1. In obese mice, it reduced body fat and increased fat oxidation by up-regulating beta-3 adrenergic receptors in white adipose tissue ^[4][5]. The acetyl-CoA carboxylase inhibition mechanism behind this was mapped in cell preparations as far back as 1983 ^[7].

Here is the direct part. The pivotal human obesity programme enrolled roughly 900 obese adults across approximately six clinical trials at doses from 0.25 mg to 54 mg daily; the trials ran up to 24 weeks. The primary endpoint — statistically significant weight loss versus placebo — was not met, and the development programme was discontinued circa 2007 ^[3]. The tolerability profile was indistinguishable from placebo ^[3]. AOD-9604 is not FDA-approved for any indication, it is prohibited in sport under WADA S2, and current 503A compounding status should be independently verified following an FDA advisory committee review in December 2024. This page summarizes what was studied; it is not advice and lists no human dose.

What it is

AOD-9604 is a synthetic hexadecapeptide — a 16-amino-acid analogue of the C-terminal lipolytic domain of human growth hormone. It models residues 177-191 of hGH with an N-terminal tyrosine substituted in place of the native phenylalanine, giving the sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe. The two cysteines form an intramolecular disulfide bridge mirroring the cystine loop of the parent hormone. It is catalogued under synonyms including AOD9604, hGH fragment 176-191, HGH frag 176-191, and Tyr-hGH(177-191).

The design intent was to isolate hGH's fat-metabolism activity while stripping away the growth-promoting, IGF-1-elevating, and diabetogenic effects of intact growth hormone. It does not bind the growth hormone receptor. It is a synthetic research peptide, not a naturally occurring molecule, and it is not an approved drug anywhere.

How it works

Two mechanisms are best documented.

Acetyl-CoA carboxylase inhibition. The earliest mechanistic work, in adipocyte and hepatocyte preparations, showed that the C-terminal part-sequence of hGH (encompassing the AOD-9604 region) inhibits acetyl-CoA carboxylase — the rate-limiting enzyme of fatty-acid synthesis — by acting through a membrane-derived second messenger that increases enzyme phosphorylation ^[7]. Less fat is made from scratch; the antilipogenic framing is more precise than the commonly used "fat-burning" label.

Beta-3 adrenergic receptor up-regulation. Chronic intraperitoneal treatment reduced body weight and fat in obese mice and increased beta-3 adrenergic receptor (beta3-AR) RNA expression in white adipose tissue. In beta3-AR knockout mice the chronic weight and lipolytic response was abolished, confirming that functional beta3-AR signaling is required for the sustained effect; a separate acute increase in energy expenditure and fat oxidation persisted even in knockout animals ^[4]. A companion study confirmed increased fat oxidation and weight loss in obese mice treated with either human GH or the modified C-terminal fragment ^[5].

Both of these mechanisms were characterized in rodent or cell models. In the human obesity programme, neither translated into a statistically significant weight-loss signal ^[3].

What the research shows

Mechanism characterization (in vitro / rodent). The synthetic lipolytic domain of hGH — AOD-9604 — was identified as the functional unit responsible for hGH's fat-metabolism effects in metabolic studies across rodent and cell models ^[6]. The mechanistic picture (ACC inhibition, beta3-AR up-regulation, fat oxidation) is coherent and reproducible in these systems ^[4][5][6][7].

Animal efficacy. Chronic treatment reduced body weight and fat in obese mice, required functional beta3-AR for sustained effects, and increased fat oxidation in direction comparable to intact hGH ^[4][5].

Preclinical safety and pharmacokinetics. Non-clinical evaluation found no genotoxic or toxicological concerns after chronic oral administration in rats and primates. Pharmacokinetics showed a very short IV half-life of approximately 3 minutes, with in vivo degradation by sequential N-terminal amino-acid removal. Oral absorption was demonstrated ^[2].

Human clinical programme. Across roughly six trials enrolling approximately 900 obese subjects, oral AOD-9604 at 0.25–54 mg daily for 7 days to 24 weeks showed a safety and tolerability profile indistinguishable from placebo. It did not produce statistically significant weight loss versus placebo, and the development programme was discontinued ^[3].

Osteoarthritis (rabbit model). One study unrelated to the obesity programme tested intra-articular injection of AOD-9604 in a collagenase-induced knee OA model in 32 New Zealand white rabbits. Weekly injection for 4-7 weeks reduced gross morphological and histopathological cartilage-degeneration scores versus saline control ^[1]. This is preclinical and represents a secondary indication distinct from the fat-metabolism story.

Reported effects, cautions & safety

Community reports compiled from peptide and biohacker forums converge on a picture consistent with the clinical trial data:

What people describe (anecdotal, not clinical evidence)

• The most common report is that people simply do not see meaningful body-fat reduction — consistent with the human trials that failed to beat placebo.
• Most users describe it as easy to tolerate with few day-to-day complaints, echoing the published tolerability finding.
• People who have used growth hormone or secretagogues often note the absence of water retention, joint puffiness, and carpal-tunnel-like tingling associated with raising IGF-1.
• A subset reports a vague lift in energy or mood; this is easily explained by expectation or concurrent diet changes and was not an endpoint the trials supported.
• Those who report any visible change almost always credit it to a calorie deficit and exercise running in parallel, making attribution to the peptide impossible.
• Community lore about localized fat loss from injecting near a stubborn area is anecdotal and biologically implausible; no human trial supports it.

Cited cautions from the literature

• AOD-9604 is not FDA-approved for any indication; all use is experimental ^[3].
• The pivotal human obesity trials did not demonstrate statistically significant weight loss; the development programme was discontinued ^[3].
• The fat-metabolism mechanisms were characterized chiefly in mouse, rat, and cell models and have not translated into a proven human fat-loss effect ^[6].
• Rodent-to-human translation failed for this compound ^[4].
• Reported human exposure ran up to roughly 24 weeks; long-term and rare risks remain uncharacterized ^[3].
• As a growth-hormone fragment, AOD-9604 is prohibited in sport under WADA S2 at all times; dedicated assays detect it even though it does not interfere with the standard hGH isoform immunoassay.
• Research-grade material from gray-market suppliers varies widely in purity and identity.

Where it fits in metabolic research

AOD-9604 is the lead on this desk and the one with the longest development history — but that history ends at a failed Phase IIb primary endpoint ^[3]. Its rodent signal is real and mechanistically coherent; its human translation is not. Read alongside Tesamorelin, which also acts on fat via the GH axis but succeeds in a narrow regulated indication, AOD-9604 illustrates how preclinical metabolic promise can fail in controlled human trials. Alongside MOTS-c, which is earlier still and awaiting human trials, it frames the desk's central question: what does it take for a metabolic peptide to cross from animal model to clinical evidence? See the comparison page for how the three line up.